Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of two pharmaceutical products: Glycyrrhizic Acid Ammonium and Sodium Ferulate Injection [1] Group 1: Product Approvals - The company has been granted a "Chemical Raw Material Drug Re-registration Approval Notice" for Glycyrrhizic Acid Ammonium, which is a raw material used for producing Glycyrrhizic Acid Ammonium Injection [1] - Additionally, the company received a "Drug Re-registration Approval Notice" for Sodium Ferulate Injection, which is used as an auxiliary treatment for ischemic cardiovascular and cerebrovascular diseases [1]

近日，重庆华森制药股份有限公司收到重庆市药监局核准签发的1个化学原料药（甘草酸二铵）的《化 学原料药再注册批准通知书》和1个药品（注射用阿魏酸钠）的《药品再注册批准通知书》。甘草酸二 铵用于生产注射用甘草酸二铵，注射用阿魏酸钠用于缺血性心脑血管病的辅助治疗。此次再注册批准将 确保相关药品正常生产和销售，公司会严格把控产品质量。不过短期内对公司经营业绩无重大影响，提 醒投资者谨慎决策，注意风险。 ...

甘草酸二铵：原料药，用于生产注射用甘草酸二铵。注射用阿魏酸钠：用于缺血性心脑血管病的辅助治 疗。 华森制药（002907）(002907.SZ)发布公告，公司于近日收到重庆市药品监督管理局核准签发的关于甘 草酸二铵化学原料药的《化学原料药再注册批准通知书》和注射用阿魏酸钠的《药品再注册批准通知 书》。 ...